Zip-Code Targeting Platform

Targeted, Modular, Effective

Our Zip-Code™ Technology platform is a first in class, cell-specific delivery system that can be used for a broad range of cell and gene therapy applications. Our experienced, dedicated and passionate team is excited to develop the next generation of targeted therapeutic products. Stay tuned for our future developments.

Contact us to learn more

Therapeutic Targeting Platform

Targeted, Flexible, Efficient

Our Zip-Code™ Technology platform is a first in class, cell-specific delivery system that can be used for a broad range of gene therapy applications. Because the Zip-Codes ™ are derived from an endogenous human mechanism it avoids all of the challenges of viral delivery approaches. The Zip-Codes ™ are universally applicable and specific for each cell type.

Our Science

Groundbreaking, Pioneering, Ushering in a New Era of Gene Therapies

Our science is redefining the boundaries of medicine, fueling new therapeutic approaches and providing a diversity of tools to oncologists and hope to families and patients with cancer.

About Us: Team and Advisors

Management Team

Anthony Johnson

Co-Founder & CEO

Anthony Johnson is an experienced executive with a strong track record of leadership across the healthcare sector. His experience has covered a multitude of areasMore details

Dr. Leon Bernal-Mizrachi

Co-Founder, CSO

Leon Bernal-Mizrachi, MD, is Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Dr. Bernal serves as theMore details

Dr. Stephen Chang Ph.D.

Senior Vice-President Research

Dr. Stephen Chang serves on the Scientific Advisory Board or Board of Directors for GT Biopharma, Orphesus Therapeutics, Cloak Therapeutics, Aegis Therapeutics and Legacy Therapeutics.More details

News & Updates


Contact Us

180 Varick Street, 6th Floor
New York, NY 10014
Emory University
1365 Clifton Road, Atlanta, GA 30322